Abiopharma

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

New Form 8-K - Eton Pharmaceuticals, Inc. Filed: 2025-06-27 AccNo: 0001437749-25-021383 Size: 166 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - BIOCRYST PHARMACEUTICALS INC Filed: 2025-06-27 AccNo: 0001171843-25-004186 Size: 240 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

BioCryst Announces Sale of European ORLADEYO®(berotralstat) Business to Neopharmed Gentili for up to $264 Million

New Form 8-K - Silence Therapeutics plc Filed: 2025-06-27 AccNo: 0001193125-25-149704 Size: 211 KB Item 5.07: Submission of Matters to a Vote of Security Holders

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Bone Biologics Files Patent Application for Bone Regeneration Technology

New Form 6-K - Haleon plc Filed: 2025-06-27 AccNo: 0001654954-25-007462 Size: 28 KB

Eton Pharmaceuticals Announces Addition to Russell2000® and Russell 3000® Indexes

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

New Form 6-K - GSK plc Filed: 2025-06-27 AccNo: 0001654954-25-007457 Size: 2 MB

NUTEX HEALTH ANNOUNCES THAT IT HAS FILED A SUPPLEMENT TO ITS PROXY STATEMENT